VISCUM

Viscum Biologics is a Turkish biotechnology company dedicated to the development of innovative vaccines and cellular therapies for infectious diseases and oncology. Founded by the prominent scientist Prof. Dr. Ercüment Ovalı, the company gained international attention for its rapid response to the COVID-19 pandemic, developing the OVIC-19 vaccine candidate and exploring the use of Dornase-alpha for severe respiratory symptoms. Their research platform integrates advanced immunology and regenerative medicine to address complex medical challenges. Viscum Biologics operates out of Istanbul, focusing on bridging the gap between academic research and clinical application. The company's pipeline includes various immunotherapy projects aimed at enhancing the body's natural defense mechanisms against cancer and viral pathogens.